Jefferies: Sarepta (SRPT) sNDA filings to set stage for 25% stock move on FDA decision
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented, "Following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
